Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
Gra19ye5a3Xr9MkJ